Oxidative stress and mitochondrial impairment after treatment with Anti-Hiv drugs: Clinical implications

Current Pharmaceutical Design

Volumn 17, Issue 36, 2011, Pages 4076-4086

  Blas García, Ana ^a,b   Apostolova, Nadezda ^a,b   Esplugues, Juan V ^a,b,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Adverse effects; Antiretroviral therapy; Cardiovascular disease; Diabetes; HIV; Lipodystrophy; Mitochondria; NNRTI; NRTI; PI; ROS

Indexed keywords

AMPRENAVIR; ANTIOXIDANT; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; GLUTATHIONE; INDINAVIR; LOPINAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; CELL DAMAGE; CELL MATURATION; CYTOTOXICITY; DIABETES MELLITUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INSULIN RESISTANCE; LIPODYSTROPHY; LIVER TOXICITY; MENTAL DISEASE; METABOLIC SYNDROME X; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT;

EID: 84855215731     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798764951     Document Type: Article

References (128)

1. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
2. Hammer SM, Eron JJ, Reiss P, Shooley RT, Thompson MA,Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS,Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS Society-USA panel. JAMA 2008; 300: 555-570.
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D'arminiomonforte A, Knysz B, Dietrich M, Philips AN, Lundgren JD, Eu-roSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
4. Panos G, Samonis G, Alexiou VG, Kavarnou GA, Charatsis G, Falagas ME. Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. Curr HIV Res 2008; 6(3): 257-260.
5. Duchen MR, Szabadkai G. Roles of mitochondria in human disease. Essays Biochem 2010; 47: 115-137.
6. Mandas A, Iorio EL, Congiu MG, Balestrieri C, Mereu A, Cau D, Dessì S, Curreli N. Oxidative imbalance in HIV-1infected patients treated with antiretroviral therapy. J Biomed Biotechnol 2009; 2009: 749-575.
7. Circu M, Aw TY. Reactive oxygen species, cellular redox systems and apoptosis. Free Radic Biol Med 2010; 46(8): 749-762.
8. Poyton RO, Ball KA, Castello PR. Mitochondrial generation of free radicals and hypoxic signaling. Trends in Endocrinology and Metabolism 2009; 20(7):332-340.
9. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552.2: 335-344.
10. Lü JM, Lin PH, Yao Q, Chen C. Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med 2010; 14(4): 840-860.
11. Wojcik M, Burzynska-Pedziwiatr I, Wozniak LA. A review of natural and synthetic antioxidants important for health and longe vity. Curr Med Chem 2010; 17(28): 3262-3288.
12. Finkel T, Hoolbrook NJ. Oxidants, oxidative stress and the biology of aging. Nature 2000; 408(6809): 239-247.
13. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39(1): 44-84.
14. Jezek P, Hlavatá L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues and organism. Int J Biochem Cell Biol 2005; 37(12): 2478-2503.
15. Cataldi A. Cellular responses to oxidative stressors. Curr Pharm Des 2010; 16(12): 1387-1395.
16. Mammucari C, Rizzuto R. Signaling pathways in mitochondrial dysfunction and aging. Mech Ageing Dev 2010; 131(7-8): 536-543.
17. Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 2009; 11(11): 2685-2700.
18. Anderson MF, Nilsson M, Eriksson PS, and Sims NR. Glutathione monoethyl ester provides neuroprotection in a rat model of stroke. Neurosci Lett 2004; 354: 163-165.
19. Rolo AP, Palmeira C.M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006; 212: 167-178.
20. Marí M, Colell A, Morales A, Caballero F, Moles A, Fernández A, Terrones O, Basañez G, Antonsson B, García-Ruiz C, Fernández-Checa JC. Mechanism of mitochondrial glutathione-dependent he-patocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 2008; 134: 1507-1520.
21. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and la-mivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42(4): 441-449.
22. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med 2011; 50(5): 567-575.
23. de Moura MB, dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 2010; 51(5): 391-405.
24. Raffaello A, Rizzuto R. Mitochondrial longevity pathways. Bio-chim Biophys Acta 2011; 1813(1): 260-268.
25. Victor VM, Apostolova N, Herance R, Hernandez-Mijares A, Ro-cha M. Oxidative stress and mitochondrial dysfunction in atherosclerosis. Curr Med Chem 2009; 16(35): 3052-3062.
26. Pellegrini M, Baldari CT. Apoptosis and oxidative stress-related diseases: the p66Shc connection. Curr Mol Med 2009; 9(3): 392-398.
27. Garcia-Ruiz C, Fernandez-Checa JC. Mitochondrial glutathione: hepatocellular survival-death switch. J Gastroenterol Hepatol 2006; 21(Suppl.3): S3-S6.
28. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24(5): 695-708.
29. Drews G, Krippeit-Drews P, Düfer M. Oxidative stress and beta-cell dysfunction. Pflugers Arch-Eur J Physiol 2010; 460(4): 703-718.
30. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107;1058-1070.
31. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: metabolic insights for a rare disorder. Journal of Endocrinology 2010; 207:245-255.
32. Kaneto H, Katakami M, Matsuhisa M, Matsuoka TA. Role of reactive oxygen species in the progression of type 2 diabetes and ath-eriosclerosis. Mediators of Inflammation 2010; 2010:453892.
33. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 2010; 16(2): 310-323.
34. Villarroya F, Domingo P, Giralt M, Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antirretroviral treatment. Biochim Biophys Acta 2010; 1801: 392-399.
35. Rial E, Rodríguez-Sánchez L, Gallardo-Vara E, Zaragoza P, Moy-ano E, González-Barroso MM. Lipotoxicity, fatty acid uncoupling and mitochondrial carrier function. Biochim Biophys Acta 2010; 1797(6-7): 800-806.
36. Nerurkar PV, Shikuma CM, Nerurkar VR. Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly active antiretroviral therapy (HAART)-associated lipodys-trophy. Clin Biochem 2001; 34(7): 519-529.
37. Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res 2007; 100: 460-473.
38. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1014-R1030.
39. Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb 2009; 16: 532-538.
40. Thomas SR, Witting PK, Drummond GR. Redox control of endo-thelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008; 10(10): 1713-1765.
41. Davidson SM. Endothelial mitochondria and heart disease. Cardio-vasc Res 2010; 88(1): 58-66.
42. Mattson MP. Apoptosis in neurodegenerative disorders. Nat.Rev.Mol.Cell.Biol. 2000; 1(2): 120-129.
43. Fernández-Checa JC, Fernández A, Morales A, Marí M, García-Ruiz C, Colell A. Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models. CNS Neurol Disor Drug Targets 2010; 9(4): 439-454.
44. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
45. Negre-Salvayre A, Coatrieux C, Ingueneau C, Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008; 153(1): 6-20.
46. Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res 2010; 35: 1295-1301.
47. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999; 15(6): 367-373.
48. Soriano V, Puoti M, García-Gascó P, Rockstroh JP, Benhamou Y, Barreiro P, McGovern B. Antiretroviral drugs and liver injury. AIDS 2008; 22: 1-13.
49. Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, Colina F, Arenas J, Solis-Herruzo JA. Defective hepatic mitocondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38(4): 999-1007.
50. Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver. Curr Med Chem 2006; 13: 2889-2900.
51. Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007; 37: 229-235.
52. Yuan L, Kaplowitz N. Glutathione in liver diseases and hepatotox-icity. Molec Aspects Med 2009; 30: 29-41.
53. Petit F, Fromenty B, Owen A, Estaquier J. Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci 2005; 26(5): 258-264.
54. Lagathu C, Eustace B, Prot M, Frantz D, Gu Y, Bastrad JP, Maachi M, Azoulay S, Briggs M, Caron M, Capeau J. Some HIV antiretro-virals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. An-tivir Ther 2007; 12(4): 489-500.
55. Chandra S, Mondal D, Agrawal KC. HIV-1 protease inhibitor induced oxidative stress supresses glucose stimulated insulin release: protection with tymoquinone. Exp Biol Med 2009; 234: 442-452.
56. Masiá M, Padilla S, Bernal E, Almenar MV, Molina J, Hernández I, Graells ML, Gutiérrez F. Influence of antirretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Clinical Therapy 2007; 29(7): 1448-1455.
57. Vassimon HS, Deminice R, Machado AA, Monteiro JP, Jordao AA. The association of lipodystrophy and oxidative stress bio-markers in HIV-infected men. Curr HIV Res 2010; 8(5): 364-369.
58. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immun Defic Syndr 2004; 35(5): 492-502.
59. Chiao SK, Romero DL, Johnson DE. Current HIV therapeutics: mechanistic and chemical determinants of toxicity. Curr Opin Drug Discov Devel 2009; 12(1): 53-60.
60. Maagaard A, Kvale D. Long term adverse effects related to nucleo-side reverse transcriptase inhibitors: clinical impact of mitochon-drial toxicity. Scand J Infect Dis 2009; 41(11-12): 808-817.
61. Day BJ, Lewis W. Oxidative stress in NRTI-induced toxicity: evidence from clinical experience and experiments in vitro and in vivo. Cardiovasc Toxicol 2004; 4(3): 207-216.
62. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 2010; 196: 311-365.
63. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and mitochondria. Biochim Biophys Acta 2006; 1757(5-6):700-707.
64. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipo-cyte as a target of anti-retroviral-induced mitocondrial toxicity. Trends in Pharmacological Sciences 2005; 26(2): 88-93.
65. Caron-Debarle M, Lagathu C, Boccara F, Vogouroux C, Capeau J. HIV-associated lipodystrophy: from fat injury to premature aging. Trends in Molecular Medicine 2010; 16(5): 218-229.
66. Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51(5): 591-599.
67. Sievers M, Walker UA, Sevastianova K, Setzer B, Wagsäter D, Eriksson P, Yki-Harvinen H, Sutinen J. Gene expression and im-munohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy. J Infect Dis 2009; 200(2): 252-262.
68. Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 2008; 13(1): 27-38.
69. Inductivo-Yu I, Bonacini M. Highly active antiretroviral therapy-induced liver injury. Cuur Drug Saf 2008; 3(1): 4-13.
70. Núñez M. Hepatotoxicty of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44: S132-S139.
71. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52(3): 1143-1155.
72. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, Schwartzapfel B, Rindler E, Fiorino AM, Zaman MT, Sax PE, Graeme-Cook F, Hibberd PL. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43(3): 365-372.
73. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adult coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585-592.
74. Lund KC, Wallace KB. Adenosine 3',5'-cyclic monophosphate (cAMP)-phosphoregulation of mitochondrial Complex I is inhibited by nucleoside reverse transcriptase inhibitors. Toxicol Appl Pharmacol 2008; 226(1):94-106.
75. de la Asunción JG, Del Olmo ML, Gómez-Cambronero LG, Sastre J, Pallardó FV, Viña J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci 2004; 76(1): 47-56.
76. Blas-García A, Apostolova N, Ballesteros D, Monleón D, Morales JM, Rocha M, Victor VM, Esplugues JV. Inhibition of mitochon-drial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010; 52(1): 115-25.
77. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Moller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J, for the D:A:D Study Group. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) Study. J Infect Dis 2010; 201(3): 318-330.
78. [78] D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Moller N, Kirk O, Pradier C, Weller, Phillips A, Lundgren J. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D Study: a multicohort collaboration. Lancet 2008; 371(9622): 1417-1426.
79. De Pablo C, Orden S, Apostolova N, Blanquer A, Esplugues JV, Álvarez A. Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregula-tion. AIDS 2010; 24(9): 1259-1266.
80. Wang X, Chai H, Lin PH, Yao Q, Chen C. Roles and mechanisms of Human Immunodeficiency Virus protease inhibitor ritonavir and other anti-human immunodeficiency cirus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary en-dothelial cells. Am J Pathol 2009; 174:771-781.
81. Balcarek K, Venhoff N, Deveaud C, Beauvoit B, Bonnet J, Kirsch-ner J, Venhoff AC, Lebrecht D, Walker UA. Role of pyrimidine depletion in the mitochondrial cardiotoxicity of nucleoside analogues reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2010; 55(5): 550-557.
82. Kohler JJ, Cucoranu I, Fields E, Green E, He S, Hoying A, Russ R, Abuin A, Johnson D, Hosseini SH, Raper CM, Lewis W. Trans-genic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy. Lab Invest 2009; 89(7): 782-790.
83. Monsuez JJ, Charniot JC, Escaut L, Teicher E, Wyplosz B, Couz-igou C, Vignat N, Vittecoq D. HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Car-diol 2009; 133(3): 293-306.
84. Thomas SR, Witting PK, Drummond GR. Redox control of endo-thelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008; 10(10): 1713-1765.
85. Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA. Vascular endo-thelial toxicity induced by HIV protease inhibitor: evidence of oxi-dant related dysfunction and apoptosis. Cardiovasc Toxicol 2004; 4: 199-206.
86. Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endotelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004; 4(3): 287-302.
87. Lefèvre C, Auclair M, Boccara F, Bastard JP, Capeau J, Vigouroux C, Caron-Debarle M. Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin. Arterioscler Thromb Vasc Biol 2010; 30(12): 2611-2620.
88. Chai H, Yang H, Yan S, Li M, Lin PH, Lumsden AB, Yao Q, Chen C. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr 2005; 40:12-19.
89. Jiang B, Hebert VY, Li Y, Mathis M, Alexander JS, Dugas TR. HIV antiretroviral drug combination induces endothelial mitochon-drial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol 2007; 224: 60-71.
90. Jiang B, Hebert VY, Khandelwal AR, Stokes KY, Dugas TR. HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. Toxicol Letters 2009; 187(3): 164-171.
91. Deng W, Baki L, Yin J, Zhou H, Baumgarten CM. HIV protease inhibitors elicit volume-sensitive CI-current in cardiac myocytes via mitochondrial ROS. J Mol Cell Cardiol 2010; 49(5): 746-752.
92. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44: 493-499.
93. Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide syn-thase expression. J Acquir Immune Defic Syndr 2005; 39(2): 152-158.
94. Adler-Wailes DC, Guiney EL, Koo J, Yanovski JA. Effects of ritonavir on adipocyte gene expression: evidence for a stress-related response. Obesity (Silver Spring) 2008; 16(10): 2379-2387.
95. Vincent S, Tourniaire F, El Yazidi CM, Compe E, Manches O, Plannels R, Roche R. Nelfinavir induces necrosis in 3T3F44-2A adipocytes by oxidative stress. J Acquir Immune Defic Syndr 2004; 37(5): 1556-1562.
96. Mulligan K, Grunfeld C, Tai V, Algren H, Pang M, Chernoff D, Lo J,Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
97. Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, Kotler DP, Parker RA, Bellamine A. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol 2009; 37(1): 65-77.
98. Hruz PW. HIV protease inhibitors and insulin resistance: lessons from in vitro, rodent and healthy human volunteer models. Curr Opin HIV AIDS 2008; 3(6): 660-665.
99. Ben-Romano R, Rudich A, Etzion S, Potashnik R, Kagan E, Greenbaum U, Bashan N. Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents. Antivir Ther 2006; 11: 1051-1060.
100. Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review. Dig Liver Dis 2006; 38(6): 363-373.
101. Sulkowski MS. Drug-induced liver injury associated with antiret-roviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38(Suppl 2): S90-S97.
102. Blas-García A, Esplugues JV, Apostolova N. Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity. Curr Med Chem 2011; 18(14): 2186-2195.
103. Pérez-Molina JA, Domingo P, Martínez E, Moreno S. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J Antimicrob Chemother 2008; 62: 234-245.
104. Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti F, Rump JA, Klinker H, Petzold D, Hartmann M. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008; 13: 343-348.
105. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, González-García M, Moltó J, Negredo E, Clotet B. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev 2009; 11(2): 103-9.
106. Jena A, Sachdeva RK, Sharma A, Wanchu A. Adverse drug reactions to nonnucleoside reverse transcriptase inhibiotr-based antir-retroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care 2009, 8(5), 318-322.
107. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsy-chiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007; 6(2): 147-54.
108. Turchan J, Pocernich CB, Gairola C, Chauan A, Schifitto G, But-terfield DA, Buch S, Narayan O, Sinai A, Geiger J, Berger JR, El-ford H, Nath A. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 2003; 60: 307-314.
109. Hulgan T, Morrow J, D'Aquila RT, Raffanti S, Morgan M, Rebeiro P, Hass DW. Oxidant stress is increased during treatment of human immunodeficiency virus infection. Clin Infect Dis 2003; 37: 1711-1717.
110. Jamaluddin MdS, Lin PH, Yao Q, Chen C. Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability in human coronary artery endothelial cells. Atherosclerosis 2010; 208: 104-111.
111. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepato-logy 2002; 35(1): 182-189.
112. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemo-ther 2007; 59(3): 342-346.
113. Brück S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, Klinker H, Petzold D, Hartmann M. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008; 13(7): 343-348.
114. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, Esplugues JV. Enhanced oxidative stress and increased mitochondrial mass during Efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol 2010; 160(8): 2069-84.
115. Manfredi R, Calza L, Chiodo F. An extremely different dysme-tabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. J Acquir Immune Defic Syndr 2005; 38(2): 236-8.
116. Negredo E, Ribalta J, Ferré R, Salazar J, Rey-Joly C, Sirera G, Masana L, Clotet B. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. AIDS 2004; 18(5): 819-21.
117. Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, Domingo JC, Mateo MG, Domingo P, Giralt M, Villarroya F. Differ-antial effects of efavirenz and lopinavir/ritonavir on human adipo-cyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 2010; 8(7): 545-553.
118. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49(11): 1603-1616.
119. Schecter AD, Berman AB, Yi L, Mosoian A, McManus CM, Ber-man JW, Klotman ME, Taubman MB. HIV envelope gp120 acti-vates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001; 98(18): 10142-10147.
120. Banerjee A, Zhang X, Manda KR, Banks WA, Ercal N. HIV proteins (gp120 and Tat) and methamphetamine in oxidative stress-induced damage in the brain: potential role of the thiol antioxidant N-acetylcysteine amide. Free Radic Biol Med 2010; 48(10): 1388-1398.
121. Fraternale A, Paoletti MF, Casabianca A, Nencioni L, Garaci E, Palamara AT, Magnani M. GSH and analogs in antiviral therapy. Mol Aspects Med 2009; 30(1-2): 99-110.
122. Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A. Hepatitis C virus induces oxidative stress, DNA damage and modulates DNA repair enzyme NEIL1. J Gastroenterol Hepatol 2010; 25(3): 627-634.
123. Baum M, Sales S, Jayaweera D, Lai S, Bradwin G, Rafie C, Page J, Campa A. Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami. HIV Med 2011; 12(2): 78-86.
124. Barbaro G, Di Lorenzo G, Soldini M, Parrotto S, Bellomo G, Bel-loni G, Grisorio B, Barbarini G. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol 1996; 91(12): 2569-2573.
125. Lin W, Wu G, Li S, Weinberg EM, Kumthip K, Peng LF, Méndez-Navarro J, Chen W-G, Jilg N, Zhao H, Goto K, Zhang L, Brock-man MA, Schuppan D, Chung RT. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NF-kB. J Biol Chem 2011; 286(4): 2665-2674.
126. Yang Y, Yao H, Lu Y, Wang C, Buch S. Cocaine potentiates astrocyte toxicity mediated by human immunodeficiency virus (HIV-1) protein gp120. PLoS One 2010; 5(10): e13427.
127. Potula R, Haorah J, Knipe B, Leibhart J, Chrastil J, Heilman D, Dou H, Reddy R, Ghorpade A, Persidsky Y. Alcohol abuse enhances neuroinflammation and impairs immune responses in an animal model of human immunodeficiency virus-1 encephalitis. Am J Pathol 2006; 168(4): 1335-1344.
128. Das SK, Vasudevan DM. Alcohol-induced oxidative stress. Life Sci 2007; 81: 177-187.